Anthony P. Adamis
#154,415
Most Influential Person Now
Anthony P. Adamis's AcademicInfluence.com Rankings
Anthony P. Adamisphilosophy Degrees
Philosophy
#8682
World Rank
#12106
Historical Rank
Logic
#5711
World Rank
#7132
Historical Rank
Anthony P. Adamisbiology Degrees
Biology
#11797
World Rank
#15221
Historical Rank
Biochemistry
#1970
World Rank
#2111
Historical Rank
Download Badge
Philosophy Biology
Why Is Anthony P. Adamis Influential?
(Suggest an Edit or Addition)Anthony P. Adamis's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Pegaptanib for neovascular age-related macular degeneration. (2004) (2145)
- Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease (2006) (1269)
- A central role for inflammation in the pathogenesis of diabetic retinopathy (2004) (1071)
- Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. (2003) (909)
- Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. (1994) (810)
- Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. (1994) (767)
- Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. (2013) (757)
- Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. (2007) (663)
- Ten years of anti-vascular endothelial growth factor therapy (2016) (657)
- VEGF INHIBITION STUDY IN OCULAR NEOVASCULARIZATION CLINICAL TRIAL GROUP. PEGAPTANIB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (2004) (657)
- Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. (1996) (626)
- Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. (2002) (593)
- A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. (2005) (584)
- Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. (1999) (565)
- Leukocyte-mediated endothelial cell injury and death in the diabetic retina. (2001) (530)
- Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. (1996) (514)
- Increased Vascular Endothelial Growth Factor Levels in the Vitreous of Eyes With Proliferative Diabetic Retinopathy (1994) (514)
- VEGF-initiated blood-retinal barrier breakdown in early diabetes. (2001) (511)
- Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. (2011) (454)
- Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. (1996) (435)
- VEGF164-mediated Inflammation Is Required for Pathological, but Not Physiological, Ischemia-induced Retinal Neovascularization (2003) (426)
- Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells. (1993) (414)
- Ocular neovascularization: an epidemiologic review. (1998) (403)
- Advanced glycation end products increase retinal vascular endothelial growth factor expression. (1998) (400)
- PRECLINICAL AND PHASE 1A CLINICAL EVALUATION OF AN ANTI-VEGF PEGYLATED APTAMER (EYE001) FOR THE TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION (2002) (387)
- VEGF164 is proinflammatory in the diabetic retina. (2003) (376)
- Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. (2002) (372)
- Diffusion of high molecular weight compounds through sclera. (2000) (367)
- The Mouse Gene for Vascular Endothelial Growth Factor (1996) (354)
- Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. (1998) (344)
- Is diabetic retinopathy an inflammatory disease? (2002) (339)
- THE ROLE OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN OCULAR HEALTH AND DISEASE (2005) (336)
- Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. (2006) (323)
- Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). (2000) (321)
- Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. (1996) (316)
- Immunological mechanisms in the pathogenesis of diabetic retinopathy (2008) (315)
- Fuchs' endothelial dystrophy of the cornea. (1993) (295)
- Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. (1997) (293)
- Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. (2006) (283)
- Sensitive blood-retinal barrier breakdown quantitation using Evans blue. (2001) (276)
- Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. (1998) (269)
- Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. (2005) (263)
- Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. (2002) (257)
- Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. (2006) (254)
- Hypoxic Induction of Endothelial Cell Growth Factors in Retinal Cells: Identification and Characterization of Vascular Endothelial Growth Factor (VEGF) as the Mitogen (1995) (251)
- Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. (2000) (250)
- Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. (2006) (249)
- Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. (2001) (245)
- Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. (1999) (240)
- Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF. (2002) (237)
- Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease (2003) (232)
- VEGF increases retinal vascular ICAM-1 expression in vivo. (1999) (214)
- Suppression of diabetic retinopathy with angiopoietin-1. (2002) (201)
- Transscleral delivery of bioactive protein to the choroid and retina. (2000) (201)
- Regulation of Vascular Endothelial Growth Factor Expression by Insulin-Like Growth Factor I (1997) (201)
- Angiogenesis inhibition in age-related macular degeneration. (1995) (197)
- Suppression of Fas‐FasL‐induced endothelial cell apoptosis prevents diabetic blood‐retinal barrier breakdown in a model of streptozotocin‐induced diabetes (2003) (196)
- The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial. (2019) (186)
- Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres. (2003) (170)
- The role of advanced glycation end products in retinal microvascular leukostasis. (2003) (167)
- Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice. (2007) (160)
- Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes: role of oxidants and protein kinase-C activation. (2003) (152)
- VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. (2004) (148)
- Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy. (2004) (146)
- Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. (1995) (139)
- Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. (2007) (135)
- Role of syndecan-1 in leukocyte-endothelial interactions in the ocular vasculature. (2002) (134)
- Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization. (2003) (132)
- Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis. (1996) (131)
- Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial (2008) (130)
- Endothelial-Directed Hepatic Regeneration After Partial Hepatectomy (2003) (115)
- Mechanisms of age-related macular degeneration. (2002) (114)
- Insulin-induced vascular endothelial growth factor expression in retina. (1999) (114)
- VEGF-A induced hyperpermeability of blood-retinal barrier endothelium in vivo is predominantly associated with pinocytotic vesicular transport and not with formation of fenestrations (2000) (110)
- Transscleral drug delivery to the retina and choroid (2002) (109)
- Rapid ocular angiogenic control via naked DNA delivery to cornea. (2001) (104)
- Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. (2007) (100)
- Angiogenesis and ophthalmic disease (2004) (99)
- Survey of patients with granular, lattice, avellino, and Reis-Bücklers corneal dystrophies for mutations in the BIGH3 and gelsolin genes. (2001) (94)
- In vivo retinal gene expression in early diabetes. (2001) (90)
- Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. (2009) (89)
- Angiostatin inhibits and regresses corneal neovascularization. (2002) (85)
- VEGF-dependent conjunctivalization of the corneal surface. (2003) (82)
- Expression and function of receptors for advanced glycation end products in bovine corneal endothelial cells. (2003) (78)
- Sustained inhibition of corneal neovascularization by genetic ablation of CCR5. (2003) (74)
- Suppression of hypoxia-associated vascular endothelial growth factor gene expression by nitric oxide via cGMP. (1999) (72)
- Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy. (2007) (72)
- Proceedings of the Third International Symposium on Retinopathy of Prematurity: an update on ROP from the lab to the nursery (November 2003, Anaheim, California). (2006) (67)
- Systemic hyperoxia decreases vascular endothelial growth factor gene expression in ischemic primate retina. (1997) (64)
- Archway Randomized Phase 3 Trial of the Port Delivery System With Ranibizumab for Neovascular Age-Related Macular Degeneration. (2021) (64)
- The inflammatory milieu associated with conjunctivalized cornea and its alteration with IL-1 RA gene therapy. (2002) (63)
- Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials (2022) (60)
- CD18 and ICAM-1-dependent corneal neovascularization and inflammation after limbal injury. (2000) (59)
- Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization. (2009) (56)
- In situ injury-induced release of basic-fibroblast growth factor from corneal epithelial cells. (1991) (55)
- The corneal epithelial stem cell. (2002) (54)
- Angiography of fluoresceinated anti-vascular endothelial growth factor antibody and dextrans in experimental choroidal neovascularization. (2000) (50)
- Platelets accumulate in the diabetic retinal vasculature following endothelial death and suppress blood-retinal barrier breakdown. (2003) (49)
- Deep Learning Predicts OCT Measures of Diabetic Macular Thickening From Color Fundus Photographs. (2019) (46)
- Mechanism of age related macular degeneration (2002) (44)
- A randomized, double-masked trial of topical ketorolac versus artificial tears for treatment of viral conjunctivitis. (2000) (44)
- Molecular biology of choroidal neovascularization. (2006) (43)
- VEGF-A induced hyperpermeability of blood-retinal barrier endothelium in vivo is predominantly associated with pinocytotic vesicular transport and not with formation of fenestrations. Vascular endothelial growth factor-A. (2000) (42)
- Avellino corneal dystrophy. (1994) (41)
- Vascular endothelial growth factor gene regulation and action in diabetic retinopathy. (2002) (41)
- Spontaneous CNV in a novel mutant mouse is associated with early VEGF-A-driven angiogenesis and late-stage focal edema, neural cell loss, and dysfunction. (2014) (40)
- Inhibition of Corneal Neovascularization by Genetic Ablation of CCR2 (2003) (39)
- Ocular Angiogenesis: Vascular Endothelial Growth Factor and Other Factors. (2016) (38)
- Matrix metalloproteinases and their inhibitors in aqueous humor. (1996) (38)
- Experimental corneal neovascularisation using sucralfate and basic fibroblast growth factor. (1996) (33)
- Assessment of the integrin alpha5beta1 antagonist JSM6427 in proliferative vitreoretinopathy using in vitro assays and a rabbit model of retinal detachment. (2010) (32)
- Antiangiogenesis agents. (2002) (26)
- Angiogenic Factors in the Development of Diabetic Iris Neovascularization and Retinopathy (1998) (25)
- Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity. (2008) (23)
- Neuronal-specific enolase in human corneal endothelium and posterior keratocytes. (1985) (23)
- Impediments to eye transplantation: ocular viability following optic-nerve transection or enucleation (2009) (22)
- The ATP-Binding Cassette Transporter ABCA 4 : Structural and Functional Properties and Role in Retinal Disease (2010) (22)
- Simultaneous but not prior inhibition of VEGF165 enhances the efficacy of photodynamic therapy in multiple models of ocular neovascularization. (2008) (22)
- Systemic antiangiogenic therapy for choroidal neovascularization. What is the role of interferon alfa? (1992) (22)
- Building on the success of anti-vascular endothelial growth factor therapy: a vision for the next decade (2020) (21)
- Treatment Options for Periorbital Hemangioma of Infancy (1992) (21)
- Inhibitory effect of an antibody to cryptic collagen type IV epitopes on choroidal neovascularization. (2004) (16)
- Anterior corneal disease of epidermolysis bullosa simplex. (1993) (16)
- Sucralfate and basic fibroblast growth factor promote endothelial cell proliferation around porous alloplastic implants in vitro. (1996) (15)
- VEGF–mediated neuroprotection in ischemic retina (2004) (13)
- Denovo development of corneal guttae and Fuchs' dystrophy in corneal grafts. (2000) (11)
- The case for complement and inflammation in AMD: open questions. (2010) (11)
- HYPOXIC REGULATION OF VASCULAR-PERMEABILITY FACTOR (VASCULAR ENDOTHELIAL GROWTH-FACTOR) MESSENGER-RNA AND PROTEIN SECRETION BY HUMAN RETINAL-PIGMENT EPITHELIAL-CELLS (1993) (10)
- THE RATIONALE FOR DRUG COMBINATIONS IN AGE-RELATED MACULAR DEGENERATION (2009) (10)
- Introducing Jayakrishna Ambati, the Recipient of the 2010 Cogan Award (2011) (10)
- The Role of Inflammation in the Pathophysiology of Diabetic Retinopathy (2008) (8)
- Inflammation and retinal disease : complement biology and pathology (2010) (8)
- Non-Invasive Tonometry in the Mouse (2003) (7)
- Shedding light on diabetic retinopathy. (1995) (6)
- VEGF164 is Pro-Inflammatory in the Diabetic Retina (2003) (6)
- Safety during the transition to phacoemulsification: a survey. (1994) (5)
- Inflammation as a Stimulus for Vascular Leakage and Proliferation (2007) (4)
- Development of the Port Delivery System with ranibizumab for neovascular age-related macular degeneration (2022) (4)
- Conjunctival concretions. (1992) (4)
- Letters to the JournalConjunctival Concretions (1992) (4)
- Pathological Retinal Angiogenesis (2010) (3)
- A Modulatory Role for Advanced Glycation End-Products (AGEs) in Retinal Microvascular Leukostasis (2002) (3)
- A Phase I Open-Label Study of Single and Repeated Doses of Intravitreal JSM6427, a Small Molecule Integrin 5β1 Antagonist, in Neovascular Age-Related Macular Degeneration (AMD) (2008) (3)
- PEY9 COST-EFFECTIVENESS MODEL FORAGE-RELATED MACULAR DEGENERATION: COMPARING MACUGEN TO VISUDYNE (2005) (3)
- VEGF Has Both Direct and Indirect Neuroprotective Effects in Ischemic Retina (2006) (3)
- VEGF Dependent Leukocyte Infiltration and Blood-Retinal Barrier Breakdown in Endotoxin-Induced Uveitis (2003) (3)
- Preclinical Evaluation of the Novel Small-Molecule Integrin (cid:2) 5 (cid:3) 1 Inhibitor JSM6427 in Monkey and Rabbit Models of Choroidal Neovascularization (2009) (3)
- Cost–Effectiveness of Macugen® versus No Treatment in Age–Related Macular Degeneration Patients (2006) (2)
- Anti-VEGF Therapy as an Emerging Treatment for Diabetic Retinopathy (2008) (2)
- Ocular Delivery of Angiostatic Agents (2004) (2)
- Medical Treatment of Diabetic Macular Edema With Rofecoxib (2005) (2)
- Brief Definitive Report 483 VEGF 164-mediated Inflammation Is Required for Pathological , but Not Physiological , Ischemia-induced Retinal Neovascularization (2017) (2)
- Transscleral Delivery of an Anti-VEGF Aptamer in a Rabbit Model (2003) (2)
- PEY11 COST-EFFECTIVENESS MODEL FORAGE-RELATED MACULAR DEGENERATION: COMPARING EARLY AND LATE MACUGEN TREATMENT (2005) (2)
- Pegaptanib sodium for the treatment of ocular vascular disease (2007) (2)
- Chapter 70 – Inhibition of angiogenesis (2010) (1)
- Reply to “FasL, leukocytes and vascular modeling” (2004) (1)
- CHAPTER 4 – Ocular angiogenesis: vascular endothelial growth factor and other factors (2010) (1)
- Non-steroid Alanti-inflammatory Drugs Prevent Early Diabetic Retinopathy: Aspirinand COX-2 Inhibition Prevent Blood-retinal Barrier Breakdown and Leukocyte Adhesion Via TNF-asuppression (2002) (1)
- Injectable PLGA-Based Formulations for Sustained Delivery of Therapeutic Agents for Intraocular Applications (2009) (1)
- Applications in the Clinic: The Anti‐VEGF Aptamer (2006) (1)
- Grading of diabetic retinopathy (2007) (1)
- Pulsatile Transscleral Drug Delivery (2002) (1)
- DIFFERENTIAL REGULATION OF VEGF/VPF AND BASIC FGF BY HYPOXIA (1994) (1)
- The dual PPAR-α/γ agonist aleglitazar attenuates retinopathy in streptozotocin diabetic rats (2013) (1)
- Capillary fenestrae formation, structure and function (2004) (1)
- Controversies in ophthalmology: Current therapies and emerging technologies (1994) (1)
- VEGF(164) governs leukocyte dynamics and pathological neovascularization (2005) (0)
- Antiangiogenic Drug Therapy for Macular Degeneration (1997) (0)
- ICAM-1 Blockade Leads to Suppression of Retinal Leukostasis in Established Diabetes (2002) (0)
- A Functional Heparin–Binding Domain is Required for Vegf164–Induced Retinal Leukostasis (2006) (0)
- PEY17 MODELING TREATMENTS FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE RELATED MACULAR DEGENERATION: COST-EFFECTIVENESS METHODS (2005) (0)
- Mural Cell Loss Following Inhibition of PDGF Signaling Enhances the Effect of Anti–VEGF Therapy on Corneal Neovascularization (2005) (0)
- Medicine, Proteomics, Bioinformatics, Materials, Pharmaceuticals, Astronomy, Transitions (2002) (0)
- Expression Patterns and Distribution of the Novel Ras Effector Protein Nore1 in Rabbit Ocular Tissues (2002) (0)
- Advanced Glycation End Products Induce Apoptosis in Corneal Endothelium (2003) (0)
- Erythropoietin Promotes Survival of Retinal Ganglion Cells in the DBA/2J Glaucoma Mouse model (2006) (0)
- People (2002) (0)
- Liquid Concepts: Liquid Architecture, the Philosophy of Gilles Deleuze and the Films of David Lynch (2013) (0)
- Cardiovascular and cerebrovascular safety of ranibizumab (RBZ) in diabetic macular edema (DME): A comprehensive patient-level meta-analysis at month 12 (2015) (0)
- Corneal Gene Therapy with IL-1 RA Inhibits Corneal Neovascularisation & Suppresses Rejection in Penetrating Keratoplasty (2002) (0)
- VEGF-A Plays a Major Retinal Neuroprotective Role in the Adaptive Response to Ischemic Injury (2007) (0)
- Pharmacological effects of hormones on the rabbit corneal endothelium in vitro (1990) (0)
- Mechanisms driving neovascularisation and microangiopathy in DR: VEGF-triggers cell adhesion via endothelial- and leukocyte-induced pathways (2008) (0)
- Eye Disease in Diabetes (2004) (0)
- Expression of Advanced Glycation End Product (AGE) Receptors in Corneal Endothelial Cells (2003) (0)
- Quantitative Measurements of Ganglion Cell Loss in a Glaucoma Mouse Model (2004) (0)
- In Vivo Transscleral Delivery of FITC-Conjugated Molecules to the Rabbit Choroid and Retina (2003) (0)
- Inflammation and retinal diseas (2013) (0)
- Judah Folkman. (2009) (0)
- Lack of Syndecan-1 Promotes Leukocyte - Endothelial Interactions in the Ocular Vasculature (2002) (0)
- Editorial (2009) (0)
- Platelet Accumulation in the Diabetic Retinal Circulation Following Fas/FasL-Induced Endothelial Apoptosis (2002) (0)
- Long-term Leukocyte-mediated Vascular Pathology in the Diabetic Retina (2003) (0)
- Encapsulation of Anti-ICAM-1 Antibodies into PLA-PEG Microspheres: In vitro and in vivo Characterization (2003) (0)
- Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Commentary. Author's reply (2007) (0)
- The Role of IGF-I in the Pathogenesis of Diabetic Retinopathy (2002) (0)
- Retina, The Journal of Retinal and Vitreous Diseases 2015 Scientific Reviewers. (2016) (0)
- Rapid Communication In Situ Injury-induced Release of Basic-fibroblast Growth Factor from Corneal Epithelial Cells (2007) (0)
- TREATING OCULAR DISORDERS (2017) (0)
- Animal Model Intrachoroidal Neovascularization in Transgenic Mice Overexpressing Vascular Endothelial Growth Factor in the Retinal Pigment Epithelium (2001) (0)
- Corneal Neovascularization: Transient Inhibition by Genetic Ablation of CCR2 and Sustained Inhibition by CCR5 Ablation (2002) (0)
- JSM6427, a Small Molecule alpha(5)beta(1) Integrin Inhibitor (2008) (0)
- VEGF RNA aptamer binding specificity and inhibition of ligand binding to VEGF receptors in vitro (2004) (0)
- VEGF164 is required for ischemia–induced retinal neovascularization in mice (2004) (0)
- Title Impediments to eye transplantation : Ocular viability followingoptic-nerve transection or enucleation (2009) (0)
- Targeting the Effect of VEGF in Diabetic Macular Edema. (2015) (0)
- CORNEAL AMYLOIDOSIS: MULTIPLE MANIFESTATIONS AND A NEW VARIANT (1995) (0)
- Angiogenic Factors and Inhibitors (2008) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Anthony P. Adamis?
Anthony P. Adamis is affiliated with the following schools:
